The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Everolimus (EVE) exposure as a predictor of toxicity (Tox) in renal cell cancer (RCC) patients (Pts) in the adjuvant setting: Results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249).
 
Timothy W. Synold
No Relationships to Disclose
 
Melissa Plets
No Relationships to Disclose
 
Catherine M. Tangen
No Relationships to Disclose
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi
Consulting or Advisory Role - Agensys
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); Celgene (Inst); Celldex (Inst); Dendreon (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Millennium (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)
 
Ganesh S. Palapattu
Stock and Other Ownership Interests - NantWorks
Consulting or Advisory Role - GenomeDx; Tokai Pharmaceuticals
Research Funding - NantWorks
Patents, Royalties, Other Intellectual Property - implantable nanotechnology for long term testosterone delivery functionalized fiducial marker for drug delivery
Travel, Accommodations, Expenses - Tokai Pharmaceuticals
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - Apton Biosystems; AstraZeneca; MolecularMD; Novartis
Research Funding - Boehringer Ingelheim
Travel, Accommodations, Expenses - Guardant Health
 
Mark N. Stein
Research Funding - Abbvie (Inst); Advaxis (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Oncoceutics (Inst)
 
Maxwell V. Meng
No Relationships to Disclose
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Exelixis; Genentech/Roche; Halozyme; Janssen; Novartis; PER; Pfizer; Sanofi; Turnstone Bio
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Polaris (Inst); TRACON Pharma (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Ian Murchie Thompson
No Relationships to Disclose
 
Christopher W. Ryan
Consulting or Advisory Role - Eisai; EMD Serono; Exelixis; Novartis
Research Funding - Argos Therapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline/Novartis (Inst); Janssen (Inst); MabVax (Inst); Merck (Inst); Morphotek (Inst); OSI Pharmaceuticals (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)